Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors

Journal of Clinical Oncology

Volumn 18, Issue 21, 2000, Pages 3677-3689

  Patnaik, Amita ^a   Warner, Ellen ^a   Michael, Michael ^a   Egorin, Merrill J ^a   Moore, Malcolm J ^a   Siu, Lillian L ^a   Fracasso, Paula M ^a   Rivkin, Saul ^a   Kerr, Ian ^a   Litchman, Manuel ^a   Oza, Amit M ^a  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; PACLITAXEL; VALSPODAR; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PERMISSIBLE DOSE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; THROMBOCYTOPENIA;

EID: 0034331497     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.21.3677     Document Type: Article

References (73)

1. Genetic and biochemical characterization of multidrug resistance
2. Clinical significance of P-glycoprotein in multidrug resistance malignancies
3. Expression of a multidrug resistance gene in human tumors and tissues
4. Expression of a multidrug resistance gene in human cancers
5. Immunohistochemical analysis of P-glycoprotein expression: Correlation with chemotherapy resistance in locally advanced breast cancer
6. Multiple-drug resistance in human cancer
7. Mitomycin C resistant L1210 leukemia cells: Association with pleiotropic drug resistance
8. Pharmacology of drugs that alter multidrug resistance in cancer
9. P-glycoprotein expression in plasma-cell myeloma is associated with resistance to VAD
10. Expression of mdr1 and mdr3 multidrug-resistance genes in human acute and chronic leukemias and association with stimulation of drug accumulation of cyclosporine
11. Clinical significance of multidrug-resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis
12. Pharmacology of drugs that alter multidrug resistance in cancer
13. Cyclosporine A and its analogues as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line
14. Clinical modulation of doxorubicin resistance by the calmodulin inhibitor trifluoperazine
15. Phase I study of vinblastine and verapamil given by concurrent IV infusion
16. Drug resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy
17. Resistance modification by PSC 833, a novel non-immunosuppressive cyclosporine A
18. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833
19. Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance-reversing cyclosporin
20. Availability of PSC 833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum
21. Reversal of multidrug resistance of SDZ PSC 833, combined with VAD (vincristine, doxorubicin, dexamethasone) in refractory multiple myeloma: A phase I study
22. SDZ-PSC 833, a non-immunosuppressive cyclosporine: Its potency in overcoming P-glycoprotein-mediated multidrug-resistance of murine leukemia
23. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative
24. Phase I study of mitoxantrone plus etoposide with multidrug blockade by SZ PSC- 833 in relapsed or refractory acute myelogenous leukemia
25. Reversal of typical multidrug resistance by cyclosporin and its non-immunosuppressive analogue SDZ PSC 833 in Chinese hamster ovary cells expressing the mdr1 phenotype
26. Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833
27. SDZ PSC 833 in combination with doxorubicin: A phase I and pharmacologic study in solid tumors
28. The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced bladder cancer
29. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance
30. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance
31. Phase I pharmacokinetic study of cyclosporine A combined with doxorubicin
32. The effect of oral SDZ PSC 833 on the pharmacokinetics (PK) of etoposide (E) during a phase I trial to modulate multidrug resistance
33. A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR)
34. Phase I trial of paclitaxel and SDZ PSC 833 in patients with solid tumors
35. Phase I trial of paclitaxel in combination with SDZ PSC 833, a multidrug resistance modulator
36. A phase I study of paclitaxel (Taxol) in combination with SDZ PSC 833, a potent modulator of multidrug resistance (MDR)
37. A phase I trial of etoposide with the oral cyclosporin SDZ PSC 833, a modulator of multidrug resistance (MDR)
38. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer
39. Reduced platelet toxicity with combination carboplatin and paclitaxel: Pharmacodynamic modulation of carboplatin associated thrombocytopenia
40. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function
41. Creatinine clearance: Bedside estimate
42. Steady-state plasma concentrations and effects of Taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer
43. Paclitaxel pharmacokinetics and pharmacodynamics
44. A program package for simulation and parameter estimation in pharmacokinetic systems
45. Effects of storage on the binding of carboplatin to plasma proteins
46. A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve
47. Clinical pharmacokinetics and pharmacodynamics of paclitaxel: A 3-hour infusion versus 24-hour infusion
48. Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (valspodar), in refractory maligancies
49. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
50. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients
51. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with non-small cell lung cancer
52. Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
53. The use of the Calvert formula to determine the optimal carboplatin dosage
54. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose sequencing study in patients with non-small cell lung cancer
55. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
56. Dose-dependent effects of PSC 833 on it tissue distribution and on the biliary excretion of endogenous substrates in rats
57. Inhibition of paclitaxel elimination in the isolated perfused rat liver by Cremophor EL
58. Limited oral bioavailability and active epithelial excretion of paclitaxel caused by P-glycoprotein in the intestine
59. The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A: Implications for drug-drug interactions and pharmacological activity of the main metabolite
60. SDZ PSC 833: A novel modulator of MDR
61. Prediction of creatinine clearance from serum creatinine
62. Comparison of Calvert versus Chatelut method for dosing carboplatin in combination with paclitaxel
63. A review of the pharmacokinetics and pharmacodynamics of combination carboplatin/paclitaxel
64. A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatinthiotepa-cyclophosphamide regimen
65. The mouse Bcrp1/Mxr/Abcp gene: Amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone and doxorubicin
66. Molecular mechanisms of multidrug resistance in cancer chemotherapy
67. Biology of multidrug-resistance in tumor cells
68. Major vault protein LRP-related multidrug resistance
69. Anti-topoisomerase drug action and resistance